iX Biopharma remains a “buy” for PhillipCapital analyst Tay Wee Kuang, with an unchanged target price of 44.5 cents, as the specialty pharmaceutical company announced that it has entered into a strategic cooperation agreement to expand its presence in China. The agreement was signed with China R...

THE following companies saw new developments that may affect trading of their securities on Wednesday.

PHARMACEUTICAL company iX Biopharma has entered into an agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG), which could pave the way for its product to be manufactured and distributed in China, the Catalist-listed company said in an exchange filing on Tuesday.

Specialty pharmaceutical company iX Biopharma has entered into a strategic cooperation framework agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) to collaborate on the sale and distribution of iX Biopharma products in China. Under the agreement, the parties will determine th...

PhillipCapital is maintaining its “buy” call on Ix Biopharma, but at a lower target price of 44.5 cents. This is down 10 cents from its previous 45.5 cent call and is expected to give the counter 81.6% returns from its 24.5 cent close on Feb 19, research analyst Tay Wee Kuang says in a note. “...

PHARMACEUTICAL company iX Biopharma has appointed a new chief commercial officer (CCO) to develop the Catalist-listed company's global commercial strategies.

Speciality pharmaceutical company iX Biopharma has appointed Eva Tan as its new chief commercial officer.  Tan previously served as iX Biopharma’s director of corporate and commercial strategy since 2019, and commercial director from 2017 to 2019. As director of corporate and commercial strat...

iX Biopharma has obtained approval and registration by the Health Sciences Authority (HSA) for Silcap, a sildenafil drug that is used in the treatment of male erectile dysfunction on Oct 20. The drug, which is iX Biopharma’s second treatment for male erectile dysfunction after Wafesil, has been de...

Phillip Securities has initiated coverage on iX Biopharma with a “buy” recommendation and target price of 45.5 cents. This comes as the brokerage believes the biotech company could finally turn profitable in FY21 as its revenue could be bumped up by as much as 250%. It notes that iX Biopharma ha...

IX Biopharma on Monday said it has obtained a licence in Australia to bring its product testing in-house, improving speed-to-market and potentially saving on testing costs.